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Abstract
This study was aimed at developing an optical molecular imaging approach to measure differences in uptake and
intracellular retention of choline in clinically isolated tissue biopsies from head and neck cancer patients. An optically
detectable analogue of choline (propargyl choline) was synthesized and evaluated in 2D and 3D models and clinically
isolated paired biopsies (n = 22 biopsies). Fluorescence contrast between clinically abnormal and normal tissues
based on uptake and intracellular retention of propargyl choline wasmeasured and correlatedwith pathologic diagnosis.
Results in 2D and 3D models demonstrated a rapid uptake of propargyl choline in cancer cells, uniform permeation in
tissuemodels, and specific detection of intracellular entrapped propargyl choline using the click chemistry reaction with
an azide-modified Alexa 488 dye. Fluorescence imagingmeasurements following topical delivery of propargyl choline in
clinically isolated biopsies showed that the mean fluorescence intensity (MFI) of neoplastic tissues was four-fold to
five-fold higher than the MFI of clinically and pathologically normal samples. This difference in fluorescence contrast
wasmeasured on the basis of comparison of paired biopsy sets isolated from individual patients aswell as comparison
of clinically abnormal and normal biopsies independent of anatomic locations in the head and neck cavity and across
diverse patients. In conclusion, a novel imaging approach based on monoalkyne-modified choline was developed and
validated using cell and tissuemodels. Results in clinically isolated tissue biopsies demonstrate a significant fluorescent
contrast between neoplastic and normal tissues and illustrate high specificity of the optical imaging approach.
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Introduction
Optical molecular imaging technology has significant potential to
improve early detection and prognostic assessment of cancer [1–3].
Advances in biophotonic instrumentation have enabled both high-
resolution and wide-field imaging of tissues in both laboratory and
clinical environment [4–7]. To develop molecular-specific optical imag-
ing approaches, we have developed a large diversity of molecular probes
such as molecular beacon–based activatable probes and nanoparticle-
based contrast agents [8–10].
Despite these significant developments, there are only limited numbers
of translational studies focused on evaluating these optical molecular
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imaging probes in clinical samples [11–15]. In a clinical environment,
positron emission tomography (PET) imaging is the leading molecular
imaging approach. Many of the clinical PET imaging methods are
based on uptake of radiolabeled small metabolites such as deoxyglucose
[16–18], choline [19,20], and thymidine [21]. On the basis of changes
in uptake of these radiolabeled metabolites, PET imaging methods
have been successful in both staging of diverse cancers and assessment
of response of tumors to therapy [22–24].
Despite significant clinical success, it is widely recognized that PET
imaging methods have limited spatial resolution [25]. In addition,
PET imaging typically requires large radioisotope generation facil-
ities at the imaging site due to short half-life (such as 110 minutes
for 18FDG PET tracer; 20 minutes for 11C-Choline) of many com-
monly used radiolabeled tracers [25].
Development of optical molecular probes that can measure the same
molecular events as detected using the current PET imaging methods
can provide a complementary imaging approach. This complementary
imaging approach cannot only address some of the limitations of PET
imaging and but also enhance fundamental understanding of disease
processes such as molecular changes in epithelial tissues during early
stages of neoplasia. Indeed, the impact of combining PET or magnetic
resonance (MR) imaging with optical molecular imaging (multimodality
molecular imaging) has been successfully demonstrated in various stud-
ies in animal model systems [26–28].
With this motivation, a molecular analogue of choline with a
monoalkyne modification (propargyl choline) was synthesized. This
analogue of choline can be detected in situ using the click chemistry
reaction with an azide-modified fluorophore. Choline is a small mole-
cule metabolite that is an essential substrate for synthesis of phospha-
tidylcholine, a major component of cell membrane [29]. Radiolabeled
choline analogues are being currently evaluated for clinical applications
in cancer detection and therapy evaluation using PET imaging [30,31].
Application of choline analogues in cancer detection is based on an
understanding that cancer cells have increased rates of uptake and
intracellular phosphorylation of choline compared to normal epithelial
cells [32,33]. The increased intracellular uptake and retention of
choline in cancer cells has also been correlated with enhanced bio-
chemical activity and expression of choline kinase enzymes and choline
transporters, respectively [32,33].
The focus of this study was to develop an optical molecular
imaging approach to measure differences in uptake and intracellular
retention of choline in clinically isolated paired (clinically abnormal
and normal tissues) fresh tissue biopsies from head and neck cancer
patients. Head and neck cancer is an excellent target for developing
and validating optical molecular imaging approaches as oral cavity is
an easily accessible site for optical imaging. Head and neck cancer,
like other epithelial-derived cancers, is initiated by molecular trans-
formation of cells in epithelial tissue that can be imaged using optical
imaging methods [34–37]. In addition, molecular contrast media can
be locally applied to suspicious lesions within the oral cavity [38,39],
thus, enabling a rapid and a noninvasive evaluation of local tissue
with molecular-specific imaging approaches.
In summary, an optically detectable analogue of choline (propargyl
choline) was synthesized and evaluated in 2D and 3D cell culture
models and clinically isolated intact fresh paired biopsies from head
and neck cancer patients. Topical application was used for delivery of
propargyl choline in a 3D tissue model and clinically isolated fresh
tissues. Following topical delivery of propargyl choline in intact fresh
tissues, the tissues were transversely sectioned, in situ stained with an
azide-modified dye, and imaged using confocal microscopy. Fluo-
rescence contrast resulting from uptake of propargyl choline was
quantified in the epithelial region of tissue sections. Results from
imaging measurements were correlated with pathologic diagnosis of
clinically isolated paired biopsies.
Materials and Methods
Cell Lines and Culture
The human cervical carcinoma cell line HeLa was maintained in a
culture medium consisting of Dulbecco’s modified Eagle’s medium
(Fisher Scientific, Pittsburgh, PA) supplemented with 10% FBS
(Fisher Scientific) and 100 mg/l penicillin (Sigma, St Louis, MO).
HeLa cells (4 × 104 cells/ml) were seeded into culture flasks, grown
in a humidified atmosphere of 5% CO2/95% air at 37°C, and sub-
cultured with 0.05% trypsin (Invitrogen, Carlsbad, CA). For im-
aging, cells were cultured on eight-well coverslip bottom cell culture
chambers (Fisher Scientific).
Tissue Phantoms
Tissue phantoms were prepared using HeLa cells embedded in a
collagen matrix. Type I collagen (Roche, South San Francisco, CA)
was dissolved in 0.2% acetic acid to a final concentration of 3 mg/ml.
To prepare tissue phantoms, a suspension of HeLa cells was spun down
and resuspended in a small volume of Dulbecco’s modified Eagle’s
medium (Invitrogen) containing 5% FBS to achieve a final concentra-
tion of 1 × 108 cells per milliliter of media. Collagen and cells were
mixed together (two parts of collagen weremixed with one part of media
with cells) to form a suspension. NaOH (1 M) was gradually added to
the suspension to achieve a final pH of 7.4. The suspension was gently
transferred into 24-mm transwells with 3.0-μm pore polycarbonate
membrane (Corning Incorporated, Corning, NY). These transwells
were then placed in individual wells of a 24-well plate with media.
Collagen-cell matrix formed a gel within 30 minutes of incubation at
37°C. After forming the gel, 40 μl of cell culture medium was added
on top of the tissue phantom. Tissue phantoms were cultured for
48 hours to develop a dense cellular network in collagen gel that mimics
both the structural features and the optical properties of oral epithelial
tissues [40].
Synthesis of Propargyl Choline
Propargyl choline was synthesized on the basis of the procedure
described by Jao et al. [41]. Four grams of propargyl bromide (80%
solution in toluene) was added to 3 g of dimethylethanolamine in
10 ml of tetrahydrofuran. The mixture was gently stirred over ice for
approximately 30 minutes. The reaction mixture was purged with
nitrogen for 24 hours. Propargyl choline (white solid) was separated
from the solvent by filtration (Millipore filter, 0.22 μm, Billerica, MA)
followed by repeated washing with tetrahydrofuran. The final product
was freeze dried and stored at −20°C.
Specificity of Detecting Propargyl Choline in Cell
Culture Models
Cells were incubated with propargyl choline (2 mM propargyl
choline was added to regular cell culture media) for 1 hour at 37°C.
Control cell samples were incubated without propargyl choline.
Both the treatment and the control samples were then washed with
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phosphate-buffered saline (PBS) and fixed with 3.7% formaldehyde.
After 30 minutes of fixation, formaldehyde solution was removed
and the cells were washed three times with 1× PBS. Both propargyl
choline labeled and control cells were incubated with the click chemis-
try reaction buffer for 30 minutes. Composition of the reaction buffer
was 0.1 M Tris buffer (pH = 8.5) with 0.05% Triton, 10 μM Alexa
488 azide, 1 mM CuSO4, and 50 mM ascorbic acid. After 30 minutes
of incubation, cells were washed with PBS and imaged using an in-
verted fluorescence microscope (IX71 Olympus Inc, Center Valley,
PA). Excitation and emission filters for fluorescence microscopy were
470 ± 15 and 515 to 550 nm, respectively. Exposure time for the
charge-coupled device (CCD) camera was 500 ms. Fluorescence images
were acquired by MetaMorph image analysis software (Olympus Inc).
Competition Assay
A competition assay was designed to demonstrate specificity of
uptake of propargyl choline through choline transporters. HeLa cells
were co-incubated with a fixed concentration of propargyl choline
(2 mM) and a varying concentration of unmodified choline (rang-
ing from 0 to 60 mM), respectively. After co-incubation of cells
with a mixture of propargyl choline and choline for 1 hour, cells
were fixed, stained, and imaged using the procedure described in
the previous section.
Specificity of Propargyl Choline Uptake in 3D Tissue
Phantom Model
To image uptake and intracellular retention of choline in epithelial
tissues, propargyl choline was topically delivered in 3D tissue phantoms
and clinically isolated biopsies (60 minutes of incubation). Following
topical delivery, tissue phantoms were rinsed and transversely sectioned
(approximately 200-μm-thick slices) using an oscillating tissue slicer
(EMS 5000, Electron Microscopy Sciences Inc, Hatfield, PA). Indi-
vidual slices were fixed using 3.7% formaldehyde in PBS at 4°C. After
30 minutes of fixation, formaldehyde was removed and the specimens
were washed three times with 1× PBS. The sliced samples were in-
cubated with the click chemistry reaction buffer as described in the
previous section. Spatial distribution of propargyl choline within a
tissue section was measured using confocal fluorescence microscopy
(Zeiss LSM 510) with a 488-nm laser excitation filter and a 500- to
550-nm band-pass emission filter.
Collection of Biopsies
Pairs of clinically normal and abnormal biopsies were obtained
from consenting patients who were scheduled for diagnostic mapping
biopsies or surgical removal of an upper aerodigestive tract tumor.
Each patient provided one clinically normal appearing biopsy and
one or two clinically abnormal appearing biopsies (2 mm to 6 mm
in diameter). The paired biopsy samples were kept fresh in cold normal
saline (0.9% NaCl) and were transported to the laboratory in less than
30 minutes.
Topical Labeling of Intact Biopsies
Clinically isolated fresh tissue biopsies were labeled with propargyl
choline using a topical application. For topical delivery, saline solution
containing 2 mM propargyl choline and 10% DMSO was applied
on the mucosal surface of clinically isolated intact biopsies. The details
of topical delivery of contrast media in isolated biopsies and resected
tumors are described in our previous studies [42]. After 60 minutes
of incubation at 37°C, the biopsies were washed in normal saline
for 10 minutes to remove any unbound propargyl choline.
Tissue Sectioning and Staining
Fresh tissue biopsies after topical delivery of propargyl choline were
transversely sectioned using an oscillating tissue slicer (EMS 5000)
to obtain 150- to 200-μm-thick fresh tissue slices. Tissue slices were
fixed, stained with Alexa 555 azide, and washed with PBS using
the same protocol as described earlier. Fluorescence and white light
[differential interference contrast (DIC)] images of transverse sections
of tissues were acquired using a laser scanning confocal fluorescence
microscope (Zeiss LSM 510) with a 543-nm laser excitation and a
535- to 590-nm emission filter.
Quantification of Imaging Data
To quantify imaging measurements in 2D cells, mean fluorescence
intensity (MFI) of individual cells within the field of view (FOV) was
calculated using ImageJ (Public domain, National Institutes of
Health). The MFI of individual cells was quantified by subtracting
the background fluorescence intensity calculated from a region on
a chamber coverslip without any cells. It is important to note that
fluorescence intensity corresponding to background fluorescence and
cellular autofluorescence was significantly small compared to the
fluorescence signal from stained cells. Multiple FOVs (typically
9–10 FOVs with approximately 90–120 cells in total) were analyzed
to calculate the MFI from three independent repeat experiments for
each of the experimental conditions. Average MFI and SD were cal-
culated for each of the experimental conditions. The MFI of transverse
sections of 3D phantoms was also calculated using ImageJ.
High-resolution fluorescence images of the isolated biopsy slices
were analyzed to quantify the MFI of clinically abnormal samples
and clinically normal samples. For quantification of the MFI, epithelial
region within the tissue section was identified on the basis of DIC
image of the transverse tissue section. The selected region identified
in the DIC image was overlaid on the corresponding fluorescence
image and the MFI of the selected region was calculated using ImageJ.
Similar approach was used in our prior studies to quantify the MFI
within the epithelial region of labeled fresh tissue sections [42]. Fluo-
rescence contrast ratio was calculated on the basis of the ratio of average
MFIs of clinically abnormal and normal biopsy samples. For calculat-
ing the average MFI, three individual images per biopsy sample were
acquired and analyzed as described above. The quantified imaging
results were statistically analyzed using analysis of variance.
Pathologic Diagnosis
Following imaging, fixed tissue sections were embedded in paraffin
and submitted for hematoxylin and eosin staining and examined by
Dr. Gandour-Edwards, a board-certified pathologist at the University
of California, Davis. The results from fluorescence imaging measure-
ments were correlated with the pathologic diagnosis.
Results
Chemical Structure of Propargyl Choline and In Situ
Labeling of Propargyl Choline in Cells
Figure 1 shows the schematic overview of intracellular uptake and
in situ labeling of propargyl choline using the click chemistry reaction.
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Propargyl choline is an analogue of choline with a monoalkyne tag
at its N terminus. Intracellular uptake of propargyl choline can be
detected on the basis of in situ labeling of propargyl choline with an
azide-modified fluorophore as illustrated in Figure 1.
Imaging Uptake of Propargyl Choline in 2D Cell Culture
and 3D Tissue Phantom Models
Results in Figure 2A demonstrate a rapid uptake (approximately
60 minutes of incubation) of propargyl choline by HeLa cells. Fluores-
cent signal based on in situ labeling of propargyl choline was predom-
inantly localized in the cytoplasm of individual cells. Prior studies have
shown that choline molecules are phosphorylated in the cytoplasm of
cells by choline kinase enzymes [43,44]. In comparison to the results
in Figure 2A, the negative control cells (not incubated with propargyl
choline but stained with Alexa 488 azide dye) show no significant
fluorescent labeling (Figure 2B).
Results in Figure 2C illustrate that topical delivery was sufficient to
achieve uniform permeation of propargyl choline across the thickness
of tissue phantoms (approximately 1-mm thickness) within 60 min-
utes of incubation. To characterize permeation of propargyl choline
in tissue phantoms, transverse sections of tissue phantoms were eval-
uated. Fluorescence contrast in transverse tissue sections was predom-
inantly localized in the cytoplasm of cells and no significant retention
and/or binding of propargyl choline with the extracellular matrix was
observed. This observation demonstrates that simple rinsing of intact
tissue phantoms with PBS buffer was sufficient to remove excess pro-
pargyl choline from the extracellular matrix of tissue phantoms. Results
of control experiments (tissue phantoms stained with Alexa 488 azide
without any prior incubation with propargyl choline) demonstrate
lack of nonspecific staining of Alexa 488 azide in tissue phantoms.
Together, these results demonstrate a rapid intracellular uptake of
propargyl choline, high specificity of the click chemistry staining reac-
tion in cells and tissue phantoms, and a uniform permeation of topical
delivered propargyl choline in tissue phantoms.
Competition Assay to Evaluate Specificity of Uptake of
Propargyl Choline
To evaluate specificity of propargyl choline uptake, a competition
assay was designed by varying the concentration of choline chloride
in cell culture medium with a fixed concentration of propargyl choline.
Results in Figure 3A show a progressive decrease in fluorescent stain-
ing of cells (resulting from decreased uptake of propargyl choline) as
the concentration of choline chloride (0–60 mM) was increased in
the extracellular environment. The results show that even a low con-
centration of choline chloride (0.2 mM, approximately 10-fold lower
than the concentration level of propargyl choline in media) was suffi-
cient to reduce uptake of propargyl choline. At concentration levels in
the range of 20 to 60 mM choline chloride (10-fold to 30-fold higher
than the concentration of propargyl choline), no detectable fluorescent
signal in cells incubated with propargyl choline was observed. Figure 3B
compares the relative MFI in individual cells as the concentration of
choline chloride was increased in the cell culture medium. These results
show that competition between propargyl choline and choline chloride
resulted in a significant decrease in uptake of propargyl choline.
Imaging Uptake of Propargyl Choline in Clinically
Normal and Abnormal Head and Neck Biopsies
Following Topical Delivery
Table 1 shows the diverse anatomic locations within the head
and neck cavity from which the paired biopsies were isolated and the
corresponding pathologic diagnosis. Nine consenting patients at UC
Davis Medical Center (UCDMC) provided 9 clinically normal biopsies
and 13 distinct clinically abnormal biopsies. When multiple abnormal
biopsies were obtained, they were collected from the same anatomic
region (e.g., both were from the base of tongue) but distinct locations
within the tumor. Although paired set of biopsies were obtained from a
variety of anatomic locations, there was a predominance of tonsillar
tissue including both palatine tonsils and the base of tongue (81% of
abnormal biopsies and 66% of normal biopsies). This reflects the cur-
rent population of patients seen in the otolaryngology clinic. Nine of
the clinically abnormal appearing samples were diagnosed as invasive
squamous cell carcinoma (SCC), which reflects the current clinical
trend that the head and neck cancers are often detected and treated
at late stages of the disease. Two biopsies were diagnosed as carcinoma
in situ (CIS). Despite appearing abnormal clinically, two biopsies were
diagnosed as normal based on the pathology review. The clinical sur-
gical pathology report concurred with the pathologic findings of these
biopsies. Patients ranged from 51 to 84 years old, and 75% were male.
All of the patients had no prior history of oropharyngeal carcinoma.
The freshly excised tissue biopsies were labeled using topical delivery
of propargyl choline. Transverse tissue sections of the labeled biopsies
were imaged as described in the Materials and Methods section. The
resulting fluorescence contrast was compared between clinically abnor-
mal and normal biopsies. Figure 4A shows a representative data for
a paired biopsy set (paired clinically abnormal and normal) isolated
from an individual patient. The data set shows fluorescence imaging
measurements of transverse tissue sections of both clinically abnormal
Figure 1. Pathway for cellular uptake and intracellular retention of propargyl choline. Intracellular retained propargyl choline can be im-
aged using the click chemistry reaction with an azide-modified fluorophore.
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Figure 2. Imaging uptake of propargyl choline in 2D cell culture and 3D tissue phantom models. Fluorescence and corresponding
white light images of HeLa cells incubated (A) with propargyl choline for 1 hour and stained with Alexa 488 azide and (B) without
propargyl choline but stained with Alexa 488 azide. (C) Propargyl choline was topically delivered in 3D tissue phantom. Fluorescence
and corresponding white light images of transverse section of tissue phantoms were acquired after fixation and staining with Alexa
488 azide. (D) Control tissue phantom was not incubated with propargyl choline but was sliced, fixed, and stained with Alexa 488 azide.
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and normal biopsies and their corresponding hematoxylin and eosin
slides with pathologic diagnosis. In this particular paired biopsy set,
the abnormal biopsy was diagnosed as invasive SCC, whereas the
paired clinical normal biopsy was diagnosed as normal based on
histologic analysis. In the cancer biopsy, significant fluorescent staining
corresponding to enhanced uptake and intracellular retention of pro-
pargyl choline by cancer cells was detected. In the normal biopsy,
negligible fluorescence staining with propargyl choline was observed.
Thus, significant differences in fluorescence contrast can be measured
between clinically abnormal and normal biopsies. Figure 4B shows com-
parison between a set of biopsies in which the clinically abnormal biopsy
was diagnosed as normal based on pathologic review. In contrast to the
results in Figure 4A, this clinically abnormal but pathologically normal
sample had similar fluorescence staining compared to the paired normal
biopsy. In both the clinically abnormal and normal samples, faint fluores-
cent staining was observed throughout the epithelial section of the tissue.
Figure 3. (A) Competition assay to characterize specificity of uptake of propargyl choline in cells. HeLa cells were co-incubated with
a fixed concentration (2 mM) of propargyl choline and increasing concentration of choline chlorine (0–60 mM). After incubation, the cells
were fixed and stained with Alexa 488 azide. (B) Decrease in MFI (corresponding to uptake of propargyl choline) as a function of increasing
concentration of choline chloride in cell culture media.
Table 1. Clinically Isolated Paired Biopsies and Their Pathologic Diagnosis.
Patient No. Clinically “Abnormal” Location Pathologic Diagnosis Clinically “Normal” Location Pathologic Diagnosis
1 Tonsil Invasive SCC Tonsil Normal
2 A and B Tonsil Invasive SCC Tonsil Normal
3 A and B Tonsil Invasive SCC Tonsil Normal
4 Tonsil Invasive SCC Base of tongue Normal
5 A and B Base of tongue CIS Base of tongue Normal
6 A and B Base of tongue Normal Base of tongue Normal
7 Floor of mouth Invasive SCC Buccal Normal
8 Hard palate Invasive SCC Buccal Normal
9 Larynx Invasive SCC Epiglottis Normal
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Comparison of Fluorescence Contrast between Clinically
Abnormal and Clinical Paired Biopsy Sets as a
Function of Pathologic Diagnosis
Figure 5A shows the relative fluorescence contrast ratio (ratiometric
contrast) of paired biopsies separated by pathologic diagnosis. The MFI
for cancer biopsies (n = 9 paired biopsies) was four-fold to five-fold
higher than theMFI of paired normal biopsies. In this study, there were
two paired biopsy sets that were diagnosed as CIS (n = 2). The MFI for
the CIS biopsies was 3.5-fold higher than the MFI of paired normal
biopsies. For the pathologically normal biopsies (initially identified as
clinically abnormal biopsies, n = 2), the MFI was similar to the MFI of
paired normal biopsies. As a result, the ratiometric contrast ratio of 1 to
1.5 was calculated for these sets of biopsies. This result demonstrates
specificity of propargyl choline–based imaging approach to distinguish
true pathologically cancer biopsy from normal biopsies. It is important
to note that many head and cancer patients are diagnosed at late stages
of the disease, so the percentage of patients detected at early stages of can-
cer (CIS and dysplasia) are significantly small and it is rare to have a clinic-
ally abnormal biopsy that is diagnosed as normal in a pathologic review.
As a result of these clinical aspects, the number of biopsies for the CIS and
normal are small for developing a statistically significant comparison.
To demonstrate potential of this imaging approach to distinguish
clinically abnormal tissues from normal tissues across diverse patients,
high-resolution imaging results were compared independent of the
paired biopsy sets and anatomic locations within the head and neck
cavity. Figure 5B shows the unpaired comparison between all can-
cerous and normal biopsies, irrespective of anatomic location within
the head and neck cavity. The results show that the MFI in cancer
Figure 4. Confocal fluorescence images (left) and corresponding pathologic diagnosis (right) of paired oral biopsy specimens topically
labeled with propargyl choline. Two representative cases of paired sets of biopsies are shown. (A) The pathologic diagnosis of the
clinically abnormal biopsy was invasive SCC, whereas the paired normal biopsy was diagnosed as normal. (B) The pathologic diagnosis
of the clinically abnormal biopsy was normal, whereas the diagnosis of the clinically normal biopsy was normal.
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biopsies is four to five times higher than the MFI of normal biopsies.
These results clearly demonstrate that cancerous tissues have a sig-
nificantly higher uptake and intracellular retention of propargyl
choline compared to normal tissues and that this difference can be
discriminated even when averaged over a heterogeneous sampling of
anatomic locations and patients.
Discussion
In this study, a monoalkyne analogue of choline (propargyl choline)
was synthesized for imaging uptake and intracellular retention of
choline in cell culture models and clinically isolated fresh tissues.
Using this nonfluorescent analogue of choline as a metabolic tracer,
uptake of propargyl choline was imaged on the basis of the click
chemistry reaction between an intracellular entrapped monoalkyne
choline and an azide-linked fluorophore. Monoalkyne modification
of choline does not significantly increase the molecular weight and
the size of native choline molecule. This is a critical factor as previous
studies [45] have shown that direct conjugation of fluorescent dyes
with small molecules can significantly influence specificity of intra-
cellular uptake of metabolites. One of the potential limitations of
the current approach is that the detection process involves a two-step
labeling procedure. In the first step, cells were incubated with pro-
pargyl choline, and in the following step, labeled cells were reacted
with an azide-functionalized fluorescent dye in the presence of copper
ions. Currently, significant research efforts are being made to develop
copper-free click chemistry probes for intracellular imaging [46,47].
These developments combined with optical imaging technologies such
as fiber optic confocal systems will enable translation of these measure-
ments to in vivo imaging in a clinical environment [48].
The results of this study demonstrate delivery of propargyl choline
in oral epithelium using topical application. These results are in agree-
ment with our previous study in which we have demonstrated efficient
topical delivery of fluorescently labeled deoxyglucose molecule in
clinically isolated biopsies and resected tumor tissues [42]. Topical
delivery of contrast media is a common approach used in many clinical
diagnostic evaluations and has significant advantages compared to the
commonly used intravenous injection [49]. Topical delivery provides a
rapid access to the target epithelial tissue. Using intravenous approach,
delivery and distribution of contrast agents is controlled by blood
circulation. Lack of vasculature in the epithelial layer on early stages
of neoplasia can limit delivery of contrast media to the target tissue.
Furthermore, topical delivery significantly reduces nonspecific inter-
action of molecular imaging probes with nontargeted tissues. There-
fore, it reduces the amount of contrast agent and the time required
for imaging. On the basis of the results of this study and our prior
studies [42], we have demonstrated that excess or unbound contrast
media can be easily removed from intact tissue biopsies by simply
rinsing the tissue with excess buffer.
High-resolution imaging results demonstrate a significant increase
in fluorescence contrast in clinically abnormal samples compared to nor-
mal samples. In the cohort of samples (n = 22 biopsies), the fluorescence
contrast was approximately four-fold to five-fold higher in clinically and
pathologically abnormal cancer biopsies compared to normal biopsies.
In addition to detecting differences between cancer and normal biopsies,
the molecular imaging approach had high specificity in identifying
normal tissue that was considered clinically abnormal based on the
clinical impression. In these paired biopsies, the clinically abnormal
appearing tissue (but pathologically normal) biopsy did not show a
significant increase in fluorescence contrast compared to the paired clin-
ically and pathologically normal tissues. This result highlights specificity
of differentiating between true clinical abnormal and normal tissues.
In summary, the results of this study have demonstrated that topi-
cally applied propargyl choline has significant potential to differen-
tiate cancerous tissues from surrounding normal tissues in a variety
of anatomic locations across a diverse group of patients.
Conclusion
The study demonstrates development and validation of a novel optical
imaging approach and its translation using clinically isolated fresh tissue
samples. Changes in uptake and intracellular retention of choline in
clinically isolated head and neck biopsies were measured using a novel
optical imaging approach. Optical molecular imaging results were
compared with pathologic diagnosis of these biopsies. The results show
that propargyl choline can be rapidly delivered to oral epithelium using
topical application. The results of this study demonstrate that optical
imaging of changes in choline uptake and intracellular retention can
Figure 5. (A) Ratiometric contrast measurement to compare the ratio of MFI resulting from uptake of propargyl choline in paired sets of
biopsies from individual patients. Results are plotted as a function of pathologic diagnosis. (B) Comparison of fluorescence contrast
in clinically isolated biopsies across multiple patients and diverse anatomic sites in oral cavity. Average fluorescence signal intensity in
clinically and histologically diagnosed normal (n = 8) and cancerous (n = 11) oral biopsy specimens labeled with propargyl choline was
quantified (**P < .001).
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distinguish between clinically normal and abnormal biopsies. Results of
imaging measurements are in agreement with pathologic diagnosis.
Overall, these results demonstrate clinical potential of the molecular
imaging approach and its application in improving detection and
prognostic evaluation of head and neck cancer.
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